Abstract 15175: Intramyocardial Bone Marrow Cell Injection in Patients with Chronic Myocardial Ischemia: Results Long Term Follow-Up
Background: Recently, using a randomized, placebo-controlled trial design, we demonstrated that intramyocardial bone marrow cell injection is associated with a beneficial effect on myocardial perfusion and left ventricular (LV) function in patients with chronic myocardial ischemia. Since only limited data are available on the long term effectiveness of bone marrow cell injection for chronic myocardial ischemia, the present study investigates whether the beneficial effects of intramyocardial bone marrow cell injection were sustained at 12 months follow-up.
Methods: Fifty patients (64±8 years, 43 male) were randomly assigned to intramyocardial injection of bone marrow cells or placebo solution. Myocardial perfusion and LV function were assessed by gated single-photon emission computed tomography at baseline and at 3 and 12 months follow-up. Canadian Cardiovascular Society angina score and quality-of-life were evaluated at baseline and at 3, 6, and 12 months.
Results: At 8 months follow-up, 1 cerebrovascular accident occurred. In the bone marrow cell group, summed stress score improved from 23.5±4.8 at baseline to 20.3±4.8 at 3 months and to 21.0±4.6 at 12 months (P<0.01). In the placebo group, a modest but significant improvement in summed stress score was observed (from 24.1±5.0 to 22.9±5.0 to 23.5±5.2 (P=0.03). The improvement in the bone marrow cell group was significantly larger as compared to the placebo group (P<0.01). LV ejection fraction increased from 53±12% at baseline to 57±12% at 3 months and to 56±12% at 12 months (P=0.01) in the bone marrow-cell group, whereas no significant changes were observed in the placebo group (54±12% vs. 53±14% vs. 53±15%, P=0.85). In addition, improvements in Canadian Cardiovascular Society angina score and quality of life were significantly greater in bone marrow cell-treated patients as compared to placebo-treated patients (both P=0.02).
Conclusion: Intramyocardial bone marrow cell injection is associated with sustained improvements in myocardial perfusion, LV function and anginal complaints.
- © 2011 by American Heart Association, Inc.